STOCK TITAN
  1. Home
  2. News
  3. ONCR

Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET. Dr. Ashburn will also present a corporate overview, which will become available for on-demand viewing on Monday, March 28, 2022 at 9:00 a.m. ET.

A live webcast of the fireside chat, as well as the on-demand corporate presentation, will be available to conference attendees from Monday, March 28 to Wednesday, March 30. Both presentations can be accessed by visiting the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) Platform and selectively self-amplifying viral RNA (vRNA)/ lipid nanoparticle (LNP) Immunotherapy Platform.

Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering selectively self-amplifying vRNA/LNP Immunotherapy Platform involves a highly innovative, novel combination of RNA and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer. Our lead IV-administered selectively self-amplifying vRNA Immunotherapy clinical candidates, ONCR-021 and ONCR-788, are both currently in IND-enabling studies.

Please visit www.oncorus.com to learn more.
           
Investor Contact:
Stern Investor Relations
Julie Seidel
Julie.seidel@sternir.com


Stock ONCR logo
Oncorus, Inc.

OTC:ONCR

ONCR Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ONCR Latest News

Jun 1, 2023
Oncorus Announces Workforce Reduction Plan
May 22, 2023
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
Mar 24, 2023
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Jan 4, 2023
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Nov 30, 2022
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

ONCR Stock Data

3.29M
23.94M
12.2%
0.02%
1.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Andover

About ONCR

mpm is an early-stage life sciences venture investing firm with a track record of identifying and building world-class companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. mpm’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders, and regenerative medicine. with its deep experience, dedicated team of operating executives, and distinguished medical and scientific advisory board, mpm is powering novel medical breakthroughs that transform patient lives.